Through binding assays, we have previously established that RFC11 directly interacts with N-recognin UBR box of UBR1, which results in inhibition of N-degron’s ubiquitin-led degradation.18 To know the fate of cancer cells’ drug sensitivity after the depletion of UBR protein, we used specific siRNA against UBR1. The gene discussed is UBR1; the disease is cancer.